Related Experiment Video
Updated: Mar 7, 2026
09:37
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
2.2K
Targeted inhibition in tumors with ALK dependency
Eunice L Kwak1, Jeffrey W Clark1, Alice T Shaw1
1Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Lung Cancer (Auckland, N.Z.)
|February 18, 2017
Summary
Anaplastic lymphoma kinase (ALK) gene translocations drive certain cancers, including non-small cell lung cancer (NSCLC). ALK inhibitors offer effective treatment for ALK-positive NSCLC, with ongoing research into resistance mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anaplastic lymphoma kinase (ALK) gene translocations were identified as oncogenic drivers in specific lymphomas and non-small cell lung cancer (NSCLC) subtypes.
- Aberrant ALK signaling is a key factor in a subset of NSCLC, particularly in never-smokers.
- The discovery of ALK's role has revolutionized treatment approaches for specific cancer populations.
Purpose of the Study:
- To review the clinicopathologic features of ALK-driven NSCLC.
- To discuss the clinical development and efficacy of anaplastic lymphoma kinase inhibitors.
- To explore the genetic basis of acquired resistance to ALK-targeted therapies.
Main Methods:
- Literature review of studies on ALK translocations in cancer.
- Analysis of clinical trial data for ALK inhibitors in NSCLC.
- Examination of genetic studies investigating resistance mechanisms to ALK inhibition.
Main Results:
- ALK inhibitors, such as crizotinib, have demonstrated significant efficacy in treating ALK-positive NSCLC patients.
- Targeted therapy leads to dramatic responses and sustained disease control in this patient group.
- Understanding resistance mechanisms is crucial for optimizing long-term treatment strategies.
Conclusions:
- Targeted inhibition of ALK represents a major advancement in personalized cancer therapy.
- Further research into resistance mechanisms will guide the development of next-generation ALK inhibitors.
- ALK-driven NSCLC serves as a model for molecularly targeted treatment strategies in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:15Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:10Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K